Pharmacogenetics and Other Molecular

Eirini Merika
, Konstantinos N Syrigos
, Muhammad Wasif Saif
West London Renal and Transplant Centre, Hammersmith Hospital, Imperial College London.
London, United Kingdom.
Oncology Unit, Third Department of Medicine, Athens Medical School. Athens, Greece.
Section of Medical Oncology, Yale University School of Medicine. New Haven, CT, USA
Among various abstracts presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago,
June 2010, four interesting abstracts focusing on pancreatic cancer merit further discussion in this post-ASCO commentary as they
potentially provide insight to clinicians and hope to patients. These abstracts point to the future of pancreatic cancer management
through identification of molecular targets and prognostic factors to overcome the limits of efficacious chemotherapy delivery.
What We Knew before ASCO 2010
Pancreatic cancer remains the most lethal, aggressive
abdominal malignancy, frequently presenting at the
metastatic stage. This renders treatment extremely
difficult, leading to poor prognosis and five-year
survival of 15% for early stage disease and life
expectancy of 6-11 months for locally advanced
disease [1]. The main challenges in the treatment of
locally advanced pancreatic adenocarcinoma are
understanding pancreatic tumour behaviour and
microenvironment, overcoming the limits of delivery
and efficacy of chemotherapy and identifying
biomarkers for prediction of outcome success.
What We Learnt at ASC0 2010
Pancreatic Microenvironment
It is well recognised that the pervasive growth of
dense, collagen-rich, fibrous tissue around pancreatic
tumours, known as the desmoplastic reaction, forms a
barrier to chemotherapy penetration and hence efficacy.
Many matrix metalloproteinases (MMPs) have been
associated with the extent of the desmoplastic reaction
as well as enhanced adhesion and invasion of
pancreatic tumours [2, 3]. Protein membrane type 1-
matrix metalloproteinase (MT1-MMP) is over-
expressed in colorectal [4] and lung tumour cells [5]
and serves as a key protein for tumour growth and
invasiveness. MT1-MMP appears to activate MMP-2,
which has a catalytic function in the basement
membrane degradation (Figure 1), leading to increased
Key words BRAF protein, human; epidermal growth factor
receptor-neu receptor; KRAS protein, human; Pancreatic
Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide
Abbreviations ASCO: American Society of Clinical Oncology;
MMP: matrix metalloproteinase; MT1-MMP: membrane type 1-
matrix metalloproteinase
Correspondence Muhammad Wasif Saif
Yale Cancer Center, Yale University School of Medicine, 333
Cedar Street, FMP 116, New Haven, CT, USA
Figure 1. Matrix degradation by MT1-MMP (with permission of
Yoshifumi Itoh Lab Imperial College. London, UK).

Page 2
JOP. J Pancreas (Online) 2010 Jul 5; 11(4):328-330.
JOP. Journal of the Pancreas - - Vol. 11, No. 4 - July 2010. [ISSN 1590-8577]
pancreatic cancer cell invasiveness but their expression
is also directly linked with the extent of the
desmoplastic reaction in pancreatic cancer tissue [6].
New evidence in the 2010 American Society of
Clinical Oncology (ASCO) Annual Meeting shows that
these MMPs may also be implicated in the tumour
microenvironment and pose an obstacle to treatment
penetration to the tumour. Krantz et al (Abstract
#4158) demonstrated that MT1-MMP over-expression
in transgenic mice led to an increase not only of pre-
cancerous lesions and metaplasia but also in tumour
invasiveness [7]. They also showed that MT1-MMP is
linked to more peripancreatic tumour fibrosis.
This study comes to support our knowledge of the role
of MMPs in tumour progression and the desmoplastic
reaction. MMPs seem to play multiple roles in tumour
progression and further investigation has the potential
of serving as a molecular target for treatment delivery.
Molecular Targets and Pancreatic Cancer
One of the most interesting studies presented at ASCO
Annual Meeting in relation to pancreatic cancer,
showed an association between certain KRAS
mutations and reduction in overall survival in
pancreatic cancer patients after surgery. Recent
research, as seen in the CRYSTAL [8], OPUS [9] and
CAIRO 2 [10] trials, suggests that genetic
polymorphisms can be used to predict treatment
outcome, such as KRAS and BRAF mutations in
colorectal cancer and response to monoclonal
antibodies against EGFR, such as cetuximab or
panitumumab. Certain mutations in particular serve as
negative predictive factors for therapy success, as
expressed in the provisional clinical opinion in the
ASCO 2009 Gastrointestinal Meeting [11]. The
KRAS/BRAF pathway has also been shown to play a
key role in the development of pancreatic ductal
adenocarcinoma [12].
The investigators from Denmark looked at the presence
of KRASBRAF and HER2 mutations in patients
operated for pancreatic adenocarcinoma and their link
to overall survival (Abstract #4043 [13]). Certain
variations in the KRAS genotype could be correlated
with a poorer overall survival (hazard ratio, HR: 1.48;
95% CI: 1.07-2.05; P=0.02). In fact the HR for overall
survival was 1.79 in patients who had certain KRAS
mutations compared to patients with normal variations
of KRAS. The majority of mutations occurred in codons
12 and 13, as in colorectal cancer patients.
Whether this gene analysis will lead to better future
treatment outcomes by targeting EGFR in the subgroup
of patients with these mutations remains to be seen.
Analysis of a single gene is unlikely to be fully
informative of the exact pharmacogenetic mechanism.
However, the results suggest it is worth pursuing the
route of analysis and genotyping of specific oncogenes
present in pancreatic cancer patients, which can
subsequently serve as molecular targets for successful
treatment. Needless to say this will be true for other
cancers, such as breast and gastric. The KRAS/BRAF
pathway has potential to serve as predictive factor for
anti-EGFR therapy in various gastrointestinal tumours.
Two papers look into the prognostic significance
between gene polymorphisms and treatment success.
One of the main challenges in the treatment of
pancreatic cancer patients is overcoming resistance to
chemotherapeutic agents. Traditional and even newer
pharmaceutical therapeutic regimens are limited in
terms of tolerance, efficacy and cross-resistance.
Resistance is multifaceted and stems from both tumour
immunosuppressive mechanisms as well as genetic
Various genes have been characterised that contribute
to tumour cell protection against immune defence
mechanisms, such as the xCT gene, which codes for
part of the plasma membrane cysteine/glutamate
transporter [14]. This balance is critical for protection
of tumour cells against the immune system [15].
In the first paper Huang et al. (Abstract #4065 [16]),
looked at the prognostic significance of single
nucleotide polymorphisms in the xCT gene in patients
with advance pancreatic cancer treated with
gemcitabine and platinum. They identified specific
polymorphisms that correlated with better overall
survival in patients receiving treatment, with maximum
median survival time of 13.6 months for specific
genotypes alone and even higher at 14.1 months in
patients receiving the combination treatment.
In the second paper Pacetti et al (Abstract #4098 [17])
exploited polymorphisms in genes involved in activity
and resistance to drugs, mainly DNA repair gene
polymorphisms, in an effort to link them to treatment
response. The substitution of Gln for Lys in position
751 of the XPD gene (Figure 2) led to increased overall
survival from 262 days (95% CI: 202-423 days) to 446
(95% CI: 346-446 days).
Figure 2. XPD protein (with permission of Department of Energy
Lawrence Berkeley National Laboratory, CA, USA).

Page 3
JOP. J Pancreas (Online) 2010 Jul 5; 11(4):328-330.
JOP. Journal of the Pancreas - - Vol. 11, No. 4 - July 2010. [ISSN 1590-8577]
Both papers suggest that genetic variants in genes like
xCT have the potential to serve as predictors of
treatment outcome and to the development of
personalised chemotherapeutic therapy.
The 2010 ASCO Annual Meeting in relation to
pancreatic cancer focuses towards the emerging field of
identification of molecular biomarkers and molecular
profiling in treatment selection and highlights the
challenges this emerging field presents. These
advances in genomic, transcriptomic and proteomic
technologies have led to a step towards materialisation
of the concept of personalised medicine. There is still a
significant gap between literature and routine clinical
practice, which needs to start bridging.
Conflict of interest The authors have no potential
conflicts of interest
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ.
Cancer Statistics, 2008. CA Cancer J Clin 2008; 58:71-96. [PMID
2. Ellenrieder V, Alber B, Lacher U, Hendler SF, Menke A, Boeck
W, et al. Role of MT-MMPs and MMP-2 in pancreatic cancer
progression. Int J Cancer 2000; 85:14-20. [PMID 10585576]
3. Määttä M, Soini Y, Liakka A, Autio-Harmainen H. Differential
expression of matrix metalloproteinase (MMP)-2, MMP-9, and
membrane type 1-MMP in hepatocellular and pancreatic
adenocarcinoma: implications for tumor progression and clinical
prognosis. Clin Cancer Res 2000; 6:2726-34. [PMID 10914717]
4. Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC,
Chambon P, Basset P. Membrane-type matrix metalloproteinase
(MT-MMP) gene is expressed in stromal cells of colon, breast, and
head and neck carcinomas. Proc Natl Acad Sci U S A 1995; 92:2730-
4. [PMID 7708715]
5. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E,
Seiki M. A matrix metalloproteinase expressed on the surface of
invasive tumor cells. Nature 1994; 370:61-5. [PMID 8015608]
6. Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J.
Association between expression of activated 72-kilodalton gelatinase
and tumor spread in non-small-cell lung carcinoma. J Natl Cancer
Inst 1993; 85:574-8. [PMID 8384265]
7. Krantz SB, Dangi-Garimella S, Shields MA, Grippo PJ, Bentrem
HG, Munshi HG. Role of MT1-MMP and Kras in invasive pancreatic
tumors with pronounced fibrosis. J Clin Oncol 2010; 28(15
8. E. Van Cutsem, I. Lang, G. D'Haens, V. Moiseyenko, J. Zaluski,
G. Folprecht, et al. KRAS status and efficacy in the first-line
treatment of patients with metastatic colorectal cancer (mCRC)
treated with FOLFIRI with or without cetuximab: The CRYSTAL
experience. J Clin Oncol 2008; 26(15 Suppl):2.
9. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG,
Volovat C, Nippgen J, et al. KRAS status and efficacy of first-line
treatment of patients with metastatic colorectal cancer (mCRC) with
FOLFOX with or without cetuximab: The OPUS experience. J Clin
Oncol 2008; 26(15 Suppl):4000.
10. Punt CJ, Tol J, C. Rodenburg CJ, Cats A, Creemers G, Schrama
JG, et al. Randomized phase III study of capecitabine, oxaliplatin,
and bevacizumab with or without cetuximab in advanced colorectal
cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer
Group (DCCG). J Clin Oncol 2008; 26(15 Suppl):LBA4011.
11. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR,
Hammond EH, Hayes DF, et al. American Society of Clinical
Oncology provisional clinical opinion: testing for KRAS gene
mutations in patients with metastatic colorectal carcinoma to predict
response to anti-epidermal growth factor receptor monoclonal
antibody therapy. J Clin Oncol 2009; 27:2091-6. [PMID 19188670]
12. Maitra A, Kern SE, Hruban RH. Molecular pathogenesis of
pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; 20:211-
26. [PMID 16549325]
13. Schultz NA, Roslind A, Heeran M, Christensen IJ, Hogdall EV,
Horn T, et al. KRAS, BRAF mutations, and HER2 expression in
patients operated for pancreatic adenocarcinomas. J Clin Oncol 2010;
28(15 Suppl):4043.
14. Lo M, Wang YZ, Gout PW. The x(c)- cystine/glutamate
antiporter: a potential target for therapy of cancer and other diseases.
J Cell Physiol 2008; 215:593-602. [PMID 18181196]
15. Lo M, Ling V, Wang YZ, Gout PW. The xc- cystine/glutamate
antiporter: a mediator of pancreatic cancer growth with a role in drug
resistance. Br J Cancer 2008; 99:464-72. [PMID 18648370]
16. Huang TJ, Li D, Weatherly J, Tang H, Gout PW, Wolff RA, et
al. Prognostic significance of xCT gene single nucleotide
polymorphisms (SNPs) in patients (pts) with advanced pancreatic
cancer (PC) treated with gemcitabine (GEM) plus platinum
analogues (PLTA). J Clin Oncol 2010; 28(15 Suppl):4065.
17. Pacetti P, Giovannetti E, Reni M, Mambrini A, Ghidini M,
Gleon L, et al. Association between DNA repair polymorphisms and
survival in pancreatic cancer patients treated with combination
chemotherapy. J Clin Oncol 2010; 28(15 Suppl):4098

There are no products listed under this category.